Thermo Fisher Scientific Consumables — Consolidated revenues increased by 6.9% to $4.68B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.9%, from $4.38B to $4.68B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates higher utilization of the company's installed equipment base and stronger recurring demand from research and clinical customers. A decrease may signal reduced laboratory activity, inventory destocking by customers, or increased competition in the consumables market.
This metric represents the total revenue generated from the sale of single-use, recurring laboratory and scientific prod...
Peers in the life sciences and diagnostics sectors typically report this as recurring revenue or consumables revenue, which is generally viewed as a high-margin, defensive growth driver compared to capital equipment sales.
tmo_segment_consumables_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $5.37B | $6.11B | $4.99B | $4.40B | $4.40B | $4.40B | $4.40B | $4.38B | $4.68B |
| QoQ Change | — | +13.7% | -18.3% | -11.9% | +0.0% | +0.0% | +0.0% | -0.5% | +6.9% |
| YoY Change | — | — | -7.1% | -28.0% | -11.9% | — | — | -0.5% | +6.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.